← All trials
NCT05173896
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2022
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2029
- First posted
- Dec 30, 2021
- Last posted
- Jun 10, 2022
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of CopenhagenLead sponsor
- Novo NordiskCollaborator
- Herlev and Gentofte HospitalOverall official - principal investigator
- University of CopenhagenCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenSponsor investigator
- Danish Research Centre for Magnetic ResonanceCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.